LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

Oncogene

Volumn 35, Issue 7, 2016, Pages 856-866

  Whang, Y M ^a   Park, S I ^b   Trenary, I A ^a   Egnatchik, R A ^a   Fessel, J P ^b   Kaufman, J M ^c   Carbone, D P ^d   Young, J D ^a,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GLUCOSE; LACTIC ACID; PROTEIN KINASE LKB1; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; STK11 PROTEIN, HUMAN;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; ENERGY METABOLISM; GLUCOSE INTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; ERLOTINIB HYDROCHLORIDE; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958744475     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.140     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-641.
3. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R et al. A novel classification of lung cancer into molecular subtypes. PLoS One 2012; 7: e31906.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
5. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
6. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575.
7. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM et al. Inactivation of LKB1/STK11 Is a common event in adenocarcinomas of the lung. Cancer Res 2002; 62: 3659-3662.
8. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810.
9. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251-262.
10. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13: 1016-1023.
11. Carretero J, Medina PP, Blanco R, Smit L, Tang M, Roncador G et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 2007; 26: 1616-1625.
12. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013; 23: 143-158.
13. Faber AC, Li D, Song Y, Liang M-C, Yeap BY, Bronson RT et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 2009; 106: 19503-19508.
14. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
15. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
17. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
18. Garassino MC, Marsoni S, Floriani I. Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin. J Clin Oncol 2011; 29: 3835-3837.
19. Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI et al. Proapoptotic BH3-Only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007; 67: 11867-11875.
20. Ling Y-H, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorl858r mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 2008; 74: 793-806.
21. Nakada D, Saunders TL, Morrison SJ. Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature 2010; 468: 653-658.
22. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007; 26: 5911-5918.
23. Kaufman JM, Amann JM, Park K, Arasada RR, Li H, Shyr Y et al. LKB1 loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT. J Thorac Oncol 2014; 9: 794-804.
24. Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 2006; 5: 1154-1165.
25. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64: 7241-7244.
26. Onozato R, Kosaka T, Achiwa H, Kuwano H, Takahashi T, Yatabe Y et al. LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci 2007; 98: 1747-1751.
27. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJF et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 2013; 3: 870-879.
28. Mahoney CL, Choudhury B, Davies H, Edkins S, Greenman C, Haaften G et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009; 100: 370-375.
29. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LGD, Neumann D et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13: 2004-2008.
30. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004; 101: 3329-3335.
31. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 2007; 403: 139-148.
32. Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha. Proc Natl Acad Sci USA 2014; 111: 2554-2559.
33. Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA. The Ca2 +/Calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 2005; 280: 29060-29066.
34. Eimer S, Belaud-Rotureau M-A, Airiau K, Jeanneteau M, Laharanne E, Véron N et al. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther 2011; 11: 1017-1027.
35. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485: 661-665.
36. Gowans GJ, Hawley SA, Ross FA, Hardie DG. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab 2013; 18: 556-566.
37. Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, Tam S et al. AMPK is a direct adenylate charge-regulated protein kinase. Science 2011; 332: 1433-1435.
38. Oakhill JS, Chen ZP, Scott JW, Steel R, Castelli LA, Ling N et al. beta-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc Natl Acad Sci USA 2010; 107: 19237-19241.
39. Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A et al. Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. Clin Cancer Res 2008; 14: 5209-5219.
40. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6: 91-99.
41. Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G, Brugge JS. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev 2011; 25: 1716-1733.
42. Murphy TA, Young JD. ETA: Robust software for determination of cell specific rates from extracellular time courses. Biotechnol Bioeng 2013; 110: 1748-1758.
43. Whang YM, Kim YH, Kim JS, Yoo YD. RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. Cancer Res 2005; 65: 3682-3690.
44. Park SI, Lee C, Sadler WD, Koh AJ, Jones J, Seo JW et al. Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res 2013; 73: 6574-6583.